USTEKINUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: RESULTS OF THE PHASE 3, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED PSUMMIT I STUDY

被引：0
|
作者：
McInnes, I. B. [1 ]
Kavanaugh, A. [2 ]
Gottlieb, A. B. [3 ]
Puig, L. [4 ]
Rahman, P. [5 ]
Ritchlin, C. [6 ]
Li, S. [7 ]
Wang, Y. [7 ]
Mendelsohn, A. M. [7 ]
Doyle, M. K. [7 ,8 ]
机构：
[1] U Glasgow, Glasgow, Lanark, Scotland
[2] U Calif, San Diego, CA USA
[3] Tufts Med Cntr, Boston, MA USA
[4] Univ Autonoma Barcelona, E-08193 Barcelona, Spain
[5] Mem U, St John, NF, Canada
[6] U Rochester, Rochester, NY USA
[7] Janssen R&D, Spring House, PA USA
[8] U Penn, Philadelphia, PA USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2013年 / 71卷
关键词：
D O I：
10.1136/annrheumdis-2012-eular.1841
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：107 / 107
页数：1
相关论文
共 50 条
  • [41] SECUKINUMAB IMPROVES SIGNS AND SYMPTOMS OF ACTIVE PSORIATIC ARTHRITIS IN A PHASE 3 RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY USING A SUBCUTANEOUS DOSING REGIMEN (FUTURE 2)
    McInnes, I. B.
    Mease, P.
    Kirkham, B.
    Kavanaugh, A.
    Ritchlin, C.
    Rahman, P.
    Van der Heijde, D.
    Landewe, R.
    Conaghan, P. G.
    Gottlieb, A. B.
    Richards, H.
    Ligozio, G.
    Pricop, L.
    Mpofu, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 352 - 353
  • [42] Efficacy and Safety Results of Guselkumab in Patients with Active Psoriatic Arthritis over 56 Weeks from a Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study
    Deodhar, Atul A.
    Gottlieb, Alice B.
    Boehncke, Wolf-Henning
    Dong, Bin
    Wang, Yuhua
    Zhuang, Yanli
    Barchuk, William
    Xu, Xie L.
    Hsia, Elizabeth
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [43] SECUKINUMAB EFFICACY IN ANTI-TNF-NAIVE AND ANTI-TNF-IR PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS OF A PHASE 3 MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY (FUTURE 2)
    Kavanaugh, A.
    McInnes, I. B.
    Hall, S.
    Chinoy, H.
    Kivitz, A.
    Kandala, S.
    Patekar, M.
    Mpofu, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 345 - 346
  • [44] Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial
    Mease, Philip J.
    Rahman, Proton
    Gottlieb, Alice B.
    Kollmeier, Alexa P.
    Hsia, Elizabeth C.
    Xu, Xie L.
    Sheng, Shihong
    Agarwal, Prasheen
    Zhou, Bei
    Zhuang, Yanli
    van der Heijde, Desiree
    McInnes, Iain B.
    LANCET, 2020, 395 (10230) : 1126 - 1136
  • [45] SULFASALAZINE THERAPY FOR PSORIATIC-ARTHRITIS - A DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
    GUPTA, AK
    GROBER, JS
    HAMILTON, TA
    ELLIS, CN
    SIEGEL, MT
    VOORHEES, JJ
    MCCUNE, WJ
    JOURNAL OF RHEUMATOLOGY, 1995, 22 (05) : 894 - 898
  • [46] Alefacept in combination with methotrexate for treatment of active psoriatic arthritis: Rationale and design of a randomized, double-blind, placebo-controlled study
    Gladman, D
    Keystone, E
    Gottlieb, A
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2004, 50 (03) : P60 - P60
  • [47] Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb study
    Mease, Philip J.
    Chohan, Saima
    Fructuoso, Ferran J. Garcia
    Luggen, Michael E.
    Rahman, Proton
    Raychaudhuri, Siba P.
    Chou, Richard C.
    Mendelsohn, Alan M.
    Rozzo, Stephen J.
    Gottlieb, Alice
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 (09) : 1147 - 1157
  • [48] Induction Therapy for Ulcerative Colitis: Results of GEMINI I, a Randomized, Placebo-Controlled, Double-Blind, Multicenter Phase 3 Trial
    Feagan, B. G.
    Rutgeerts, P. J.
    Sands, B. E.
    Colombel, J.
    Sandborn, W. J.
    Colombel, J.
    Hanauer, S. B.
    Van Assche, G. A.
    Axler, J.
    Kim, H.
    Danese, S.
    Fox, I.
    Milch, C.
    Sankoh, S.
    Wyant, T.
    Xu, J.
    Parikh, A.
    GASTROENTEROLOGY, 2012, 142 (05) : S160 - S161
  • [49] Efficacy and safety of Guselkumab through 2 years: Results from a phase 3, randomized, double-blind, placebo-controlled study conducted in biologic-naive patients with active psoriatic arthritis
    McInnes, I.
    Rahman, P.
    Gottlieb, A.
    Hsia, E.
    Kollmeier, A.
    Xu, X.
    Sheng, S.
    Jiang, Y.
    Shawi, M.
    Chakravarty, S.
    van der Heijde, D.
    Mease, P.
    EXPERIMENTAL DERMATOLOGY, 2021, 30 : 38 - 38
  • [50] Phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group study of ustekinumab in patients with Takayasu arteritis
    Yoshifuji, Hajime
    Ishii, Tomonori
    Ohashi, Hiroki
    Yoshizawa, Katsunori
    Mihoya, Maki
    Nishikawa, Kazuko
    Nakaoka, Yoshikazu
    RHEUMATOLOGY ADVANCES IN PRACTICE, 2025, 9 (02)
12345